Beyond the management of risk factors as described in the current guideline38 (eg, treating hypertension or encouraging smoke cessation), and treating appropriate patients with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or β-blockers, these patients might also benefit from a follow-up through longitudinal serial measurement of natriuretic peptides. This evidence concerns the gene ACE and hypertensive disorder.